Skip to main content
SpringerLink
Log in

Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The aim and objective of the study is to compare the efficacy of conditioning regimens with or without high-dose radiotherapy for treating aggressive non-Hodgkin’s lymphoma (NHL). Eighty-nine aggressive NHL patients who underwent high-dose therapy in combination with autologous stem cell transplantation (HDT/ASCT) between 1993 and 2006 were retrospectively studied. HDT was either high-dose chemotherapy alone (CT) or high-dose chemoradiotherapy (CRT). Overall, 37 patients in CT group and 52 in CRT group. The median radiotherapy DT in CRT group was 8 Gy. The median count of reinfused CD34+ cells was 6.26 × 106 and 22.16 × 106 cells/kg, respectively (p < 0.001). The median time of leukocyte engraftment was 11 days in CT group and 13 days in CRT group (p = 0.003), and the median platelet engraftment time was 12 days in CT group and 11 days in CRT group (p = 0.305). The median event-free survival (EFS) was 102 and 84 months in CT and CRT groups, respectively (p = 0.783), and the median overall survival (OS) was 102 and 121 months in CT and CRT groups, respectively (p = 0.857). Prolonged hospitalization favored EFS (p = 0.013) and OS (p = 0.011). In conclusion, when compared with CT, high-dose CRT does not improve prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stiff P, Dahlberg S, Forman S, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens—a Southwest Oncology Group trial. J Clin Oncol. 1998;16:48–55.

    Article  CAS  PubMed  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. doi:10.1056/NEJM199512073332305.

    Article  CAS  PubMed  Google Scholar 

  3. Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol. 2004;15:1504–9. doi:10.1093/annonc/mdh391.

    Article  CAS  PubMed  Google Scholar 

  4. Xh He, Yk Shi, Xh Han, et al. Autologous peripheral blood stem cell transplantation in the treatment of patients with primary large mediastinal B-cell lymphoma. Chin J Oncol. 2003;25(6):592–5.

    Google Scholar 

  5. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol. 2000;18:332–9.

    Article  CAS  PubMed  Google Scholar 

  6. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 2000;96(7):2399–404.

    CAS  PubMed  Google Scholar 

  7. Aristei C, Tabilio A. Total-body irradiation in the conditioning regimens for autologous stem cell transplantation in lymphoproliferative diseases. Oncologist. 1999;4:386–97.

    CAS  PubMed  Google Scholar 

  8. Portlock CS, Rosenberg SA, Glatstein E. Kaplan HS: treatment of advanced non-hodgkin’s lymphomas with favorable histologies: preliminary results of a prospective trial. Blood. 1976;47(5):747–56.

    CAS  PubMed  Google Scholar 

  9. Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91(9):3148–55.

    CAS  PubMed  Google Scholar 

  10. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21:897–906. doi:10.1200/JCO.2003.07.113.

    Article  PubMed  Google Scholar 

  11. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:2208–14. doi:10.1200/JCO.2005.05.158.

    Article  CAS  PubMed  Google Scholar 

  12. Park S, Brice P, Noguerra M, et al. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2000;26:321–6. doi:10.1038/sj.bmt.1702510.

    Article  CAS  PubMed  Google Scholar 

  13. Bhatia S, Ramsay NKC, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87(9):3633–9.

    CAS  PubMed  Google Scholar 

  14. Verdonck LF, WLJv Putten, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1995;332(16):1045–51. doi:10.1056/NEJM199504203321601.

    Article  CAS  PubMed  Google Scholar 

  15. Blay J-Y, Gomez F, Sebban C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood. 1998;92(10):3562–8.

    CAS  PubMed  Google Scholar 

  16. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol. 2001;19:406–13.

    Article  CAS  PubMed  Google Scholar 

  17. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350(13):1287–95. doi:10.1056/NEJMoa031770.

    Article  CAS  PubMed  Google Scholar 

  18. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study. J Clin Oncol. 2000;18(16):3025–30.

    Article  CAS  PubMed  Google Scholar 

  19. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-hodgkin’s lymphoma: randomized phase III EORTC study. J Natl Cancer Inst. 2001;93(1):22–30. doi:10.1093/jnci/93.1.22.

    Article  CAS  PubMed  Google Scholar 

  20. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev. 2007;33(4):338–46. doi:10.1016/j.ctrv.2007.02.002.

    Article  CAS  PubMed  Google Scholar 

  21. Liu K, Lu D. Clinical analysis of autologous peripheral blood stem cell transplantation in 182 patients with non-Hodgkin’s lymphoma. Chin J Oncol. 2002;41(6):363–6.

    Google Scholar 

  22. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–96.

    Article  CAS  PubMed  Google Scholar 

  23. Zhou L, Sun Y, Tan W, et al. The clinical, pathological analysis for 1125 cases with non—Hodgkin’s lymphoma. Oncol Prog. 2006;4(5):391–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China

    Yi Niu, Yuankai Shi, Shengyu Zhou, Feng Pan, Shikai Wu, Peng Liu, Jiangliang Yang, Xiaohong Han & Xiaohui He

Authors
  1. Yi Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuankai Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengyu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shikai Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiangliang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaohong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaohui He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuankai Shi.

About this article

Cite this article

Niu, Y., Shi, Y., Zhou, S. et al. Study of conditioning regimens with or without high-dose radiotherapy before autologous stem cell transplantation for treating aggressive lymphoma. Int J Hematol 89, 106–112 (2009). https://doi.org/10.1007/s12185-008-0217-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0217-x

Keywords

Search

Navigation